
RYBREVANT Delivers Sustained Benefit in Difficult Colorectal Cancer Cases
Longer-Term OrigAMI-1 Results Highlight Durable Activity of Amivantamab-Based Regimens in Metastatic Colorectal Cancer Johnson & Johnson has announced encouraging longer-term follow-up results from the Phase 1b/2 OrigAMI-1 clinical study evaluating amivantamab-vmjw, an investigational bispecific antibody targeting both epidermal growth factor…








